Table 1 Summary of input data used in the model
Subgroup | Value (lower and upper CI) | Reference |
|---|---|---|
Baseline risk of hospitalisation | ||
CHD infants | 9.7% (7.4%, 12.0%)† | Feltes et al. 2003 [5] |
CLD infants | 12.8% (8.8%, 16.8%)† | IMPACT, 1998 [6] |
Preterm: <29 wGA | 10.00% (0.7%, 19.3%)† | MedImmune/Abbott, Data on File. |
Preterm: 29–32 wGA | 7.69% (2.86%, 12.5%)† | MedImmune/Abbott, Data on File. |
Preterm: 33–35 wGA | 7.69% (2.86%, 12.5%)† | MedImmune/Abbott, Data on File. |
Relative risk reduction of RSV hospitalisation with palivizumab prophylaxis | ||
CHD infants | 45.3% (18.1%, 63.4%)† | Feltes et al. 2003 [5] |
CLD infants | 38.5% (5.0%, 60.2%)† | IMPACT, 1998 [6] |
Preterm: <29 wGA | 80.39% (0.00%, 96.26%)† | MedImmune/Abbott, Data on File. |
Preterm: 29–32 wGA | 79.69% (35.38%, 93.62%)† | MedImmune/Abbott, Data on File. |
Preterm: 33–35 wGA | 73.16% (54.87%, 93.09%)† | MedImmune/Abbott, Data on File. |
Mortality rates of children hospitalised due to RSV disease | ||
CHD infants | 3.72% (1.19%, 6.23%)† | Wang et al. 2008 [14] |
CLD infants | 4.00% (3.00%, 5.00%)† | Wang et al. 2008 [14] |
Preterm infants | 0.43% (0.23%, 0.63%)† | Wang et al. 2008 [14] |
Life expectancy | ||
CHD infants | 76.0 years (75.0††, 78.9††)‡ | Office for National Statistics [25] |
All other subgroups | 79.0 years (77.9††, 82.0††)‡ | Office for National Statistics [25] |
Risk of RSV-related sequelae | ||
Increase in resource use | 2 years | Greenough et al. 2001 [24] |
Decrease in utility | 5 years | Greenough et al. 2004 [21] |
Drug and administration costs | ||
Palivizumab (50 mg vial) | £306.64/pack (£6.13/mg) | MIMS [27] |
Palivizumab (100 mg vial) | £563.64/pack (£5.64/mg) | MIMS [27] |
Initial administration by hospital nurse | £41 (£23, £47) | Costs of Health and Social Care 2009–2010 [29] |
Subsequent administration by GP practice nurse | £31 (£26, £36) | Costs of Health and Social Care 2009–2010 [29] |
Rate of hospital admissions for RSV (% of patients) | ||
CHD children in general ward | 100% | Assumption |
CHD children in Intensive Care Unit (ICU) | 38.14% (28.48%, 47.81%)† | Feltes CSR [16] |
All other infants; General ward | 100% | Assumption |
All other infants; Intensive Care Unit (ICU) | 27.45% (18.79%, 47.81%)† | FDA - Palivizumab Clinical Review [2] |
Length of stay of hospital admissions for RSV patients | ||
CHD children in general ward | 12.40 (9.30, 18.99§) ‡ | FDA - Palivizumab Clinical Review [2] |
CHD children in Intensive Care Unit (ICU) | 15.19 (11.39, 15.50§)‡ | FDA - Palivizumab Clinical Review [2] |
All other infants; General ward | 6.64 (4.98, 8.32§)‡ | FDA - Palivizumab Clinical Review [2] |
All other infants; Intensive Care Unit (ICU) | 7.04 (5.28, 8.80§)‡ | FDA - Palivizumab Clinical Review [2] |
Cost per day of RSV hospitalisation | ||
General ward | £555¶ (£406*, £1,955*) | NHS National Schedule of Reference Costs [28] |
Intensive Care Unit (ICU) | £2,225 ¶ (£311*, £1,954*) | NHS National Schedule of Reference Costs [28] |
Medical cost of sequelae (recurrent wheeze/asthma) | ||
Annual per patient cost for all other subgroups | £14, 015 | Greenough et al., 2004 [21]; Costs of Health and Social Care 2009–2010 [29]; NHS National Schedule of Reference Costs [28] |
Annual per patient cost for 33–35 wGA | £810 (£0, £8,972) | Shefali-Petal et al., 2011 [22] |
Health state utility values (Utility (SE); (Lower and upper CI) | ||
Non RSV-H patients | 0.95 (0.25)†; (0.03, 1.00‡‡) | Greenough et al., 2004 [21] |
Patients admitted with RSV-H | 0.88 – Modelled as 7.37% (0.94%) reduction†; (5.53%, 9.21%§) | Greenough et al., 2004 [21] |